New treatment for inborn error of metabolism
Nature Medicine
July 26, 2010
Combined treatment with two drugs, metronidazole and N-acetylcysteine, is effective in treating children with ethylmalonic encephalopathy ― a birth defect of the metabolism that affects the gastrointestinal, circulatory, and nervous systems. The article in this week's Nature Medicine suggests that this therapy may be useful in the treatment of children suffering from the genetic disorder.
Ethylmalonic encephalopathy is caused by mutations in a mitochondrial protein important for metabolizing sulfide. As sulfide is largely a product of intestinal microbes, Massimo Zeviani and colleagues tested the effect of an antibiotic ― metronidazole ― together with N-acetylcysteine ― a precursor of the sulfide-buffering molecule ― in mice and in patients with this disease.
The treatment substantially prolonged the lifespan of mice carrying disease-causing mutations and resulted in marked clinical improvement in five affected children, with no adverse effects. A larger clinical trial will now be necessary to confirm these encouraging results.
doi: 10.1038/nm.2188
Research highlights
-
Aug 5
Microbiology: Single switch makes Escherichia coli beneficial insect partnerNature Microbiology
-
Aug 5
Conservation: More than half of unassessable species may be at risk of extinctionCommunications Biology
-
Aug 4
Physiology: Restoring cellular functions in pigs after deathNature
-
Aug 3
Zoology: Mother’s iron helps Weddell seal pups diveNature Communications
-
Aug 2
Health: Certain medications may impact risk of heat-related heart attacksNature Cardiovascular Research
-
Jul 28
Archaeology: Ancient humans were consuming milk long before they could digest itNature